4/16/2013 11:04:09 AM
AUBAGNE, France & GOETTINGEN, Germany--(BUSINESS WIRE)--From the first quarter of 2013 onwards, Sartorius Stedim Biotech (Paris:DIM) will adopt a few slight changes to its reporting in order to follow established international reporting practice and thus to provide financial data in the best comparable manner. Relevant changes relate to amortization as well as to other taxes, which are now shown under functional expenses. Moreover, going forward underlying EBITDA will be used as the key performance indicator instead of underlying EBITA, which has been used so far. However, these changes to cost allocations do not influence the net result of the group. This fact sheet translates Sartorius Stedim Biotech’s business figures for 2012 as well as its earnings guidance for 2013 according to these changes.
comments powered by